Skip to main content
. Author manuscript; available in PMC: 2022 Jul 22.
Published in final edited form as: Nat Rev Urol. 2022 Mar 9;19(5):305–320. doi: 10.1038/s41585-022-00571-8

Fig. 4 |. Timeline of CDK4/6 inhibitor development and approval of systemic therapies for renal cell carcinoma.

Fig. 4 |

Timeline showing milestones in the development and FDA approval of cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors (above)12–14,21,22. Also, FDA approval of various systemic and targeted therapies for the treatment of advanced and metastatic renal cell carcinoma (RCC, below) is shown3–5,8–10. TKI, tyrosine kinase inhibitor.